Sept. 5, 2024 - Prolocor, Inc. and Slingshot Biosciences recently announced the publication in Bioanalysis of the results from their analytic validation testing titled: "Assessing Prognosis by Quantifying FcγRIIa on Fixed Platelets."
“Prolocor is excited to advance this new prognostic tool to guide clinical decision making. The results of our validation studies show this innovative test demonstrates outstanding intra (2 percent) and inter (10 percent) test variation, well below the current FDA guidance (25 percent)," said Dr. David Schneider Prolocor Co-Founder and Chief Science Officer. “We want to thank our partners at Slingshot Biosciences for developing the novel TruCytes cell mimics that are central to the test and pivotal to demonstrating the accuracy and power of this test.”
"Congratulations to Dr. Schneider and his team for their exceptional work advancing this important prognostic tool. We are thrilled that Prolocor's use of Slingshot Biosciences' TruCytes cell mimics enabled precise and accurate results that outperformed biological controls," said Dr. Jeffrey Kim, Founder and CEO of Slingshot Biosciences. "This study highlights the power of our cell mimic platform in driving next-generation tests that could enhance patient care."
"Clinicians need better tools to guide decision making on the choice of antiplatelet therapy in coronary artery disease patients, particularly after coronary stenting. The Prolocor pFCG test will be an important asset as we tailor antiplatelet therapies to balance thrombotic and bleeding risk" said Dominick J. Angiolillo, MD, PhD, FACC, FESC, FSCAI, Professor of Medicine, Chief, Division of Cardiology, Director, Thrombosis Research Center, University of Florida, College of Medicine-Jacksonville.
For more information, please visit the company website at www.prolocor.com and www.slingshotbio.com.
November 07, 2024 
